Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 12:2018:2403935.
doi: 10.1155/2018/2403935. eCollection 2018.

Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies

I-Tsu Chyuan  1   2 , Ji-Yih Chen  3   4
Affiliations
Review

Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies

I-Tsu Chyuan et al. Mediators Inflamm. .

Abstract

Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Further evidence from human and animal studies have defined that IL-17 and IL-17-producing cells contribute to tissue inflammation, autoimmunity, and host defense, leading to the following pathologic events associated with SpA. Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. In this review article, we have discussed the contributing role of IL-17 and different IL-17-producing cells in the pathogenesis of SpA and provided an outline of therapeutic application of the IL-17 blockade in the treatment of SpA. Other targeted cytokines associated with IL-17 axis in SpA will also be included.

PubMed Disclaimer

References

    1. Dougados M., Baeten D. Spondyloarthritis. The Lancet. 2011;377(9783):2127–2137. doi: 10.1016/S0140-6736(11)60071-8. - DOI - PubMed
    1. McHugh K., Bowness P. The link between HLA-B27 and SpA—new ideas on an old problem. Rheumatology. 2012;51(9):1529–1539. doi: 10.1093/rheumatology/kes061. - DOI - PubMed
    1. Vandenbroeck K. Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies. Journal of Interferon & Cytokine Research. 2012;32(4):139–151. doi: 10.1089/jir.2011.0103. - DOI - PMC - PubMed
    1. Appel H., Maier R., Wu P., et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Research & Therapy. 2011;13(3, article R95) doi: 10.1186/ar3370. - DOI - PMC - PubMed
    1. Vidal-Castiñeira J. R., López-Vázquez A., Diaz-Peña R., et al. A single nucleotide polymorphism in the Il17ra promoter is associated with functional severity of ankylosing spondylitis. PLoS One. 2016;11(7, article e0158905) doi: 10.1371/journal.pone.0158905. - DOI - PMC - PubMed

MeSH terms